Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Get Free Report) insider Dan Karlin sold 6,774 shares of the company’s stock in a transaction that occurred on Tuesday, December 26th. The shares were sold at an average price of $3.63, for a total value of $24,589.62. Following the completion of the sale, the insider now owns 365,030 […]
Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Get Free Report) have been given an average rating of “Buy” by the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have covered the […]
Mind Medicine Inc. said Thursday a Phase 2 trial testing LSD as a treatment for generalized anxiety disorder met its main goal, showing a statistically.
Mind Medicine (MindMed) (NASDAQ:MNMD – Get Free Report) is scheduled to be announcing its earnings results after the market closes on Thursday, November 2nd. Analysts expect the company to announce earnings of ($0.65) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link. Mind […]
Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Get Free Report) have received an average recommendation of “Buy” from the eight research firms that are covering the company, Marketbeat.com reports. Eight research analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have updated their coverage on […]